Table 1.
The pathophysiological findings in RPMI8226-RFP-FLuc myeloma-bearing mice
| Treatment group | Number of mice with paralysis (Total = 23 mice) |
RPMI8226-RFP-FLuc BLI signal | Serum M-protein level (human λ light chain) |
Number of mice with plasmacytoma (Total = 23 mice) |
|
|---|---|---|---|---|---|
| Skeletal regions | Nonskeletal regions | ||||
| No treatment | 23 | Very high | Low | Very high | 17 |
| eNKs | 17 | High | Low | High | 7 |
| Dara | 18 | Very high | Low | Very high | 14 |
| Dara + eNKs | 16 | Medium | Low | Medium | 7 |
| Dvd | 12 | Low | BDL | Low | 5 |
| Dvd + eNKs | 9 | Very low | BDL | Very low | No |
BLI bioluminescence imaging, eNKs expanded natural killer cells, Dara daratumumab, Dvd daratumumab, bortezomib, and dexamethasone, BDL below the detection level